1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Proteonomix, Inc.

Proteonomix, Inc.

PROT
Proteonomix, Inc.US flagOther OTC
0.00
USD
- -
- -
791.00Market Cap
1997 Y
1998 Y
1999 Y
2000 Y
2001 Y
2002 Y
2008 Y
2009 Y
2010 Y
2011 Y
TTM
Revenue per Share
1,034.61
1,455.98
298.46
143.53
24.82
5.33
0.06
0.04
0.02
- -
- -
Basic EPS, GAAP
-41.32
-117.27
-455.22
-311.27
-53.15
105.4
-2.33
-1.16
-0.75
-0.21
-0.21
Free Cash Flow per Basic Share
-189.05
-248.39
-246.96
-49.63
1.03
-28.65
-0.05
-0.06
-0.17
-0.05
-0.18
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-215.89
-300.02
-724.73
-957.71
-970.52
-388.5
-5.65
-4.78
-4.18
-3.17
-2.82
Tangible Book Value per Share
139.3
210.9
-151.43
-461.83
-488.28
-30.22
-3.5
-1.36
-1.48
-1.04
-0.47
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
2
3
5
7
7
Sales/Revenue/Turnover
12
21
5
3
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-0.19
-6.29
-130.49
-212.72
-197.58
-308.55
-3,677.73
-2,695.96
-4,140.7
-5,026.72
-22,967.96
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-2
-7
-6
-1
4
-5
-4
-3
-1
-2
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-3.99
-8.05
-152.52
-216.87
-214.16
1,977.94
-3,763.64
-2,723.68
-4,164.66
-5,321.67
-9,554.4
Working Capital
2
1
-1
-8
-7
-1
-8
-5
-7
-7
-4
LT Debt
2
1
2
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
5
4
- -
-6
-7
-1
-7
-4
-3
-4
-1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
8.5
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Dec'11
Mar'12
Jun'12
ST Debt
3
3
3
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
8
8
Market Capitalization
- -
2
- -

Working Capital

FRC

•

in mil. unless spec.
Dec'11
Mar'12
Jun'12
Total Current Assets
- -
4
3
Cash, Cash Equivalents & STI
- -
3
2
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
7
7
6
Payables & Accruals
3
3
3
ST Debt
3
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
88.3%
7.4%
Free Cash Flow
- -
-1,130.05%
-59.58%
Net Income, GAAP
- -
-165.25%
-60.12%
Sales/Revenue/Turnover
- -
-38.84%
-68.79%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2010
- -
- -
- -
- -
- -
2011
- -
- -
- -
- -
- -
2012
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2010
-0.2
-0.2
-0.13
- -
-0.75
2011
-0.06
-0.04
-0.06
- -
-0.21
2012
-0.28
0.18
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2010
- -
- -
- -
- -
- -
2011
- -
- -
- -
- -
- -
2012
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Michael Moshe Cohen
Full Time Employees
164
Sector
Healthcare
Industry
Biotechnology
Address
145 Highview Terrace Hawthorne NJ United States of America 07506
IPO Date
Jul 31, 1997
Website
proteonomix.com
Similar Companies
InflaRx N.V. (IF0.DE)
Phio Pharmaceuticals Corp. (PHIOW)
Cardax, Inc. (CDXI)
Kexing Biopharm Co., Ltd. (688136.SS)
YD Bio Limited Warrants (YDESW)
Algorae Pharmaceuticals Limited (1AI.AX)
Business
Proteonomix, Inc. (PROT) is a biotechnology company focused on developing therapeutics based on human cells and their derivatives, including non-embryonic stem cells. The company offers Proteoderm, an anti-aging skin cream utilizing a proprietary matrix of proteins to reduce wrinkles; UMK-121, a treatment for liver disease that mobilizes bone marrow stem cells through approved drugs; and StromaCel, a therapy for cardiac patients post-myocardial infarction using donor bone marrow-derived stem cells administered intravenously to repair heart tissue. Through subsidiaries such as Proteoderm, Inc., a wholly-owned entity formed in 2008 for protein synthesis and anti-aging skincare; StromaCel, Inc.; PRTMI; and THOR Biopharma, Proteonomix targets cardiovascular disease, liver disease, type 1 diabetes, and cosmeceuticals. Founded in 1995 and headquartered at 145 Highview Terrace, Hawthorne, New Jersey, the company operates primarily in the United States with historical efforts to expand internationally via joint ventures, including negotiations in the United Arab Emirates and Europe for regenerative medicine facilities under the PRTMI model. Recent activities include ongoing development of stem cell-based modalities without major funding rounds, acquisitions, or new product launches reported in the last 1-2 years, alongside a 2013 restructuring that formed a BVI entity for technology sublicensing to support financing.